At a time of global transition for life sciences, with China stepping up the pace of innovation and the U.S. adopting protectionist policies, the health innovation region in Catalonia, Spain, is emerging as one of the most dynamic hubs in Europe. Last year, the region, centered on Barcelona, saw growth of 8.3% over 2024, and there are now 1,650 companies, including 423 biotechs, 259 digital health specialists and 238 med techs.
Biopharma and med-tech companies raising money in public or private financings, including: Bioventrix, Cingulate, Gelmedix, Levee, Liminatus, Mainz, Newron, Q32.
After 118 years as a private company, dermatology specialist Leo Pharma A/S is poised to complete an IPO after reporting a full-year net profit for the first time since 2018.
Biopharma and med-tech companies raising money in public or private financings, including: Berlin Heals, Biorestorative, Entirety, Nektar, Neupulse, Neurent, Xilio.
Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment.
After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor.
Ascletis Pharma Inc. raised HK$843.53 million (US107.93 million) in a placement on the Hong Kong Stock Exchange to advance its lead program, ASC-30, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist that can be dosed once monthly subcutaneously and once daily orally for treating obesity.
RSS
.webp?height=488&t=1770931675&width=650 "Interleukin 17 (IL-17)")
